Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Epargny Metz-Tessy, France Clinical Trials

A listing of Epargny Metz-Tessy, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (21) clinical trials

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: relapsed/refractory follicular lymphoma (FL) patients relapsed/refractory aggressive (DLBCL) lymphoma patients relapsed/refractory other indolent (iNHL) ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu ) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support. Subjects will be followed for 56 days.

Phase

0.61 miles

Learn More »

Pembrolizumab in Untreated Extensive SCLC

This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in ED-SCLC. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the informed consent, and then centrally randomized 1:1 to the experimental arm ...

Phase

0.61 miles

Learn More »

Short Duration Treatment of Non-severe Community Acquired Pneumonia

To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), ...

Phase

0.61 miles

Learn More »

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Currently, there is no standard treatment for patients with recurrent or refractory peripheral T-cell lymphoma who relapse after a first line of cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (CHOP) treatment. Chemotherapies such as gemcitabine are used as monotherapy but the results alone are insufficient. In addition, there is no approved monotherapy ...

Phase

0.61 miles

Learn More »

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

This trial will be a prospective French nationwide study analyzing the effect of treatment with azacitidine in patients with MDS-associated SAID with steroid dependence and/or resistance, and its correlation with possible changes in immunological parameters

Phase

1.59 miles

Learn More »

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

After surgery, most of patients with advanced ovarian/primitive peritoneal /fallopian carcinoma received as first line treatment, carboplatin plus paclitaxel plus or minus bevacizumab for 6 cycles followed by surveillance or bevacizumab maintenance therapy up to one year (GOG (Burger et al.), ICON7 (Perren et al.), French national guidelines Saint Paul ...

Phase

1.59 miles

Learn More »

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Immune chekpoints (ICI) are evaluated in many digestive cancers. Certain types of cancer appear to be rather refractory to ICI such as colorectal cancers (CRC). However, the MSI CRC representing approximately 15% of the CRCs exhibits a high mutational load which generates many potentially immunogenic neoantigens. In addition, strong expression ...

Phase

1.59 miles

Learn More »

Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

Standard management of castration-resistant metastatic prostate cancer is represented by chemotherapy with Docetaxel 75 mg/m every 3 weeks combined with Prednisone since a symptomatic and overall survival benefit was demonstrated. Although this benefit is independent of age in the study by Tannock (cut-off:69), it does not seem possible to extrapolate ...

Phase

1.59 miles

Learn More »

Study Of Nivolumab Alone Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses. : In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based response), patients ...

Phase

1.59 miles

Learn More »